stockrow
Friday 6 November 2026
Export KLRS’s income statement to Excel — free account
Kalaris Therapeutics Inc.
KLRS Healthcare Biotechnology
- EPS
- +21.3%
- Free cash flow
- +11.9%
Quarter to June 2026, against a year earlier
2.44
0.08
+3.39%
Follow KLRS
Alert me
Kalaris Therapeutics Inc. (KLRS) P/E ratio
Kalaris Therapeutics Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 22.3× (April 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
Against its own ten years
Low 0.0×
High 22.3×
Ten-year median
0.0×
Current reading's percentile
88
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KLRS Kalaris Therapeutics Inc. | n/m |
| HRTX Heron Therapeutics, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. compare | n/m |
| PLRX Pliant Therapeutics, Inc. compare | n/m |
| INKT MiNK Therapeutics, Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| VRCA Verrica Pharmaceuticals Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)